EUVIMEDSkopri EUVIMED
Open access

4H‐CRCXL Mitigates RasV12‐Induced Phenotypes in Glioblastoma Model of Drosophila

Pradeep Kumar iD, Vaishali Raghuvanshi, Prabhat Kumar, Rohit Kumar, Brijesh Singh Chauhan, Diksha Katiyar, Saripella Srikrishna

Molecular Carcinogenesis · 2026

DOI: 10.1002/mc.70161 ↗

At a glance

Journal article in Molecular Carcinogenesis, 2026. Written by Pradeep Kumar and 6 co-authors. Institution: Cancer and Neurobiology Laboratory, Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India. Major MEDLINE topics: Glioblastoma, Brain Neoplasms, Benzopyrans, Antineoplastic Agents. 78 references. The full text is freely available in PubMed Central.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Glioblastoma (GBM), a Grade IV malignant brain tumor, accounts for over half of all gliomas and remains resistant to current therapies, requiring the development of novel treatment strategies. Aberrant Ras signaling and PI3K/Akt hyperactivation and RAF/MEK/ERK pathways are major oncogenic drivers, implicated in approximately 30% of cancers, including GBM. Chromenes, particularly 4H‐chromenes, possess diverse anticancer activities, but their application in GBM remains limited. In this study, we evaluated the efficacy of a novel chromene derivative, ethyl 4‐(3,5‐dichloro‐2‐hydroxyphenyl)‐5,7‐dihydroxy‐2‐methyl‐4H‐chromene‐3‐carboxylate (4H‐CRCXL), using a Drosophila melanogaster model of RasV12‐driven gliomagenesis. In silico docking revealed strong interactions of 4H‐CRCXL with Ras, p‐Akt, p‐ERK, and Bcl‐2, suggesting multi‐targeted inhibition. In vivo administration of 4H‐CRCXL resulted in significant phenotypic rescue, improved CNS morphology, enhanced survival, and attenuated RAS‐driven tumor phenotypes. The compound suppressed glial hyperproliferation, reduced oxidative stress, restored metabolic homeostasis, and induced apoptosis, demonstrating a broad spectrum of anticancer effects. These findings highlight 4H‐CRCXL as a promising lead compound for targeting RAS‐driven gliomagenesis and support its further evaluation in mammalian glioma models.

Subjects

MeSH terms (MEDLINE)

GlioblastomaBrain NeoplasmsBenzopyransAntineoplastic AgentsAnimalsDrosophila melanogasterDisease Models, AnimalPhenotypeHumansSignal TransductionApoptosisras ProteinsProto-Oncogene Proteins c-akt

Author keywords

4H‐CRCXLDrosophilaPI3K/AktRAF/ERKRasV12apoptosisglioblastoma

Substances

BenzopyransAntineoplastic Agentsras ProteinsProto-Oncogene Proteins c-akt

Authors and institutions

  • Cancer and Neurobiology Laboratory, Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
  • Department of Chemistry, MMV, Banaras Hindu University, Varanasi, Uttar Pradesh, India.

ORCID profiles: Pradeep Kumar

Cite

APA

Kumar, P., Raghuvanshi, V., Kumar, P., Kumar, R., Chauhan, B. S., Katiyar, D., & Srikrishna, S. (2026). 4H‐CRCXL Mitigates RasV12‐Induced Phenotypes in Glioblastoma Model of Drosophila. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70161

Vancouver

Kumar P, Raghuvanshi V, Kumar P, Kumar R, Chauhan BS, Katiyar D, et al. 4H‐CRCXL Mitigates RasV12‐Induced Phenotypes in Glioblastoma Model of Drosophila. Molecular Carcinogenesis. 2026. doi:10.1002/mc.70161

BibTeX
@article{Kumar2026,
  author = {Kumar, Pradeep and Raghuvanshi, Vaishali and Kumar, Prabhat and Kumar, Rohit and Chauhan, Brijesh Singh and Katiyar, Diksha and Srikrishna, Saripella},
  title = {4H‐CRCXL Mitigates RasV12‐Induced Phenotypes in Glioblastoma Model of Drosophila},
  journal = {Molecular Carcinogenesis},
  year = {2026},
  doi = {10.1002/mc.70161}
}
Start for free →